Farmitalia Carlo Erba S.r.l.

Genetica

Farmitalia Carlo Erba

Vascular Laboratory, Inc.

Paolo Sarmientos

Jean-Francois Mayaux

Martine Latta

Antonella Isacchi

Giampaolo Nitti

Emanuela Scacheri

Michael Knapp

Laura Bergonzoni

Georges Brefort

Pierre Monsan

Gaetano Orsini

Romeo Roncucci

Francois Paul

Guy Mazue

Philippe De Taxis Du Poet

Anna Brandazza

Philippe De Du Poet

Gilles Cauet

Didier Betbeder

Production of human prourokinase

The present invention relates to anti-thrombin polypeptides isolated from the leech Hirudinaria manillensis and to processes for their preparation. The polypeptides of the invention may be modified by way of amino acid extension at either or each end, and may be subjected to post-translational modification. The anti-thrombin polypeptides may be prepared by isolating them from the tissue or secretions of the leech Hirudinaria manillensis but they also may be synthetized by recombinant DNA methods. According to this latter aspect, the invention provides DNA sequences, expression vectors and host cell lines for the recombinant preparation of the polypeptides. The anti-thrombin polypeptides of the invention find an useful application in the treatment of venous thrombosis, vascular shunt occlusion and thrombin-induced disseminated intravascular coagulation.

Anti-thrombin polypeptides

Anti-thrombin polypeptides and pharmaceutical compositions thereof

The present invention relates to the production, by recombinant DNA techniques, of derivatives of basic fibroblast growth factor (bFGF). These derivatives of bFGF can act as antagonists and/or superagonists of the wild type molecule in the angiogenic process. These derivatives, as well as wild type bFGF, may be prepared by the use of strains or E. coli which have been transformed with plasmids carrying nucleotide sequence coding for human and bovine bFGF and their derivatives.

Deletion mutant of basic fibroblast growth factor and production thereof

Process for the enzymatic preparation of basic fibroblast growth factor

The present invention provides a polypeptide which is capable of binding specifically human basic fibroblast growth factor and human acidic fibroblast growth factor, a DNA sequence which encodes the polypeptide of the invention and a vector which incorporates a DNA sequence of the invention and which is capable, when provided in a transformed host, of expressing the polypeptide of the invention encoded by the DNA sequence. A host transformed with such a vector forms part of the invention also.

Extracellular form of the human fibroblast growth factor receptor

Mature human serum albumin is produced from a human serum albumin produced by a microbiological route in the form of fused protein ('pseudo-pro-HSA') containing an N-terminal peptide elongation.

Process for the preparation of mature human serum albumin

Human serum albumin is made by culturing a bacterium (e.g. E. coli) capable of providing for the stable maintenance of a plasmid containing an inducible promoter (e.g. P.sub.trp), a ribosome binding site (e.g. that of the CII gene of bacteriophage lambda not containing the t.sub.R1 sequence), and the human serum albumin gene possessing an ATG initiation codon at the 5' end.

Process for the microbiological preparation of human serum albumin

Human serum albumin is produced by culturing a bacterium (e.g. E. coli) capable of maintaining a plasmid containing an inducible promoter (e.g. P.sub.trp) upstream of the penicillin amidase promoter, the ribosome binding site of the penicillin amidase gene and the penicillin amidase signal peptide, fused with the structural gene for human serum albumin.

Growing community of inventors

Milan, Italy

Paolo Sarmientos